|

Cetuximab/avelumab Clinical Trials

1 actively recruiting trial

Pipeline

Phase 2: 1

Top Sponsors

  • Gruppo Oncologico del Nord-Ovest1

Indications

  • Metastatic Head and Neck Cancer1
  • Recurrent Head and Neck Cancer1
  • Head and Neck Squamous Cell Carcinoma (HNSCC)1
  • Cancer1

Other1 trial

Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treatment for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients With a PD-L1 Combined Positive Score (CPS)≥1≤19.
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.